ss-31 peptide clinical trials 18 clinical trials of SS-31 in humans - SS-31 peptidekidney clinical trials Unveiling the Potential of SS-31 Peptide: A Deep Dive into Clinical Trials and Therapeutic Applications

SS-31 clinicaltrial The SS-31 peptide, also known by its generic name elamipretide, has emerged as a significant area of research in the development of novel therapeutic strategiesFDA approves drug for treatment of rare mitochondrial disorder. This mitochondria-targeting peptide is garnering considerable attention due to its potential to address a wide range of conditions characterized by mitochondrial dysfunction. The exploration of SS-31 peptide clinical trials reveals a promising landscape for treating age-related diseases, genetic disorders, and acute injuries.

Understanding the Mechanism of Action

At its core, SS-31 is a tetrapeptide with a unique ability to localize within mitochondria.作者：C Wang·2025·被引用次数：3—Moreover,clinical trials are underway for SS31, which is showing potential in managing mitochondrial myopathies and Barth syndrome [30,31]. Given SS31's ... Its primary mechanism of action involves interacting with cardiolipin, a crucial phospholipid component of the inner mitochondrial membraneCardiac Mitochondrial Dysfunction:Clinical studies demonstrate SS-31's efficacy in: Significant enhancement in cardiac function in Barth syndrome and heart .... This interaction allows SS-31 to modulate mitochondrial function by enhancing electron transport chain efficiency, improving ATP production, and reducing the generation of reactive oxygen species (ROS). This antioxidant peptide plays a vital role in protecting cells from oxidative stress and promoting cellular energy productionCardiac Mitochondrial Dysfunction:Clinical studies demonstrate SS-31's efficacy in: Significant enhancement in cardiac function in Barth syndrome and heart .... Research has demonstrated that SS-31 treatment reduces Aβ production, highlighting its potential in neurodegenerative conditions[Retracted] Mitochondrial‐Targeted Antioxidant Peptide .... Furthermore, SS-31 has been shown to protect both the cardiovascular and nervous systems from stress-induced dysfunction.SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ...

A Spectrum of Clinical Applications

The therapeutic potential of SS-31 peptide is being investigated across a diverse array of medical conditions.In preclinical orclinical studies, elamipretide increases mitochondrial respiration, improves electron transport chain function and ATP production, and reduces ... Clinical studies have explored its efficacy in:

* Cardiac Diseases: Clinical trials in heart failure have been a significant focus, with SS-31's efficacy in cardiac mitochondrial dysfunction being a key area of investigation. Studies suggest that SS-31 therapy effectively protects the heart against various forms of damage.

* Mitochondrial Disorders: SS-31 is currently under clinical trials for multiple mitochondrial disorders, including primary mitochondrial myopathy and Barth syndrome. The FDA has even approved a first-of-its-kind mitochondrial therapy, elamipretide (brand name FORZINITY™ for Barth syndrome), underscoring the therapeutic significance of this peptide class. Clinical studies demonstrate SS-31's efficacy in significant enhancement in cardiac function in Barth syndrome and heart failure2025年9月25日—The FDA has approved a first-of-its-kind mitochondrial therapy in the U.S. for the treatment of Barth syndrome, a rare condition that causes ....

* Kidney Disease: Research indicates that SS-31 peptide can ameliorate kidney damage.作者：X Kuang·2017·被引用次数：47—We demonstrated thatSS-31modified PLGA NPs improved the protection efficiency of GGA against gentamicin-induced hair cell damage in zebrafish. SS-31 treatment improved age-related mitochondrial morphology and glomerulosclerosis, suggesting a role in chronic kidney disease.作者：W Zhao·2019·被引用次数：186—Peptide SS-31upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia.

* Neurological Conditions: SS-31 emerges as a promising therapeutic candidate to attenuate neurodegeneration pertinent to alpha-synuclein misfolding and aggregation. Peptide SS-31 is also being studied for its protective effects in conditions affecting the nervous system.

* Ischemia and Injury: The peptide has shown promise in protecting tissues from damage caused by ischemia, such as in acute kidney injury and after spinal cord injury (SCI)[Retracted] Mitochondrial‐Targeted Antioxidant Peptide .... SS31 therapy effectively protects the heart against damage induced by transverse aortic constriction-induced hypertrophic cardiomyopathy.

* Aging-Related Conditions: Clinical studies on SS-31 support its use as a treatment for multiple aging-related changes, including those related to cognition and physiology.

Insights from Clinical Trials and Studies

The body of evidence from clinical trials and scientific study provides valuable insights into the performance and safety of SS-312024年7月11日—SS-31 emerges as a promising therapeutic candidateto attenuate neurodegeneration pertinent to α-synuclein misfolding and aggregation.. A systematic analysis of 18 clinical trials of SS-31 in humans offers a comprehensive overview of both successful and unsuccessful outcomes. While some clinical trials in heart failure and primary mitochondrial myopathy have failed, the overall trajectory of research remains positive, with ongoing investigations into its therapeutic benefitsApplication research of novel peptide mitochondrial ....

Notably, elamipretide increased exercise performance after 5 days of treatment in patients with primary mitochondrial myopathy (PMM) without increased safety concerns.作者：X Du·2024·被引用次数：41—Systematically analyze18 clinical trials of SS-31 in humans, offering a comprehensive overview of both successful and unsuccessful results, contributing to ... This highlights the potential for improved physiological function.

Safety and Dosage Considerations

Regarding safety, SS-31 treatment leads to a few adverse events, though mostly mild. In the context of Forzinity™ (elamipretide), the most common side effects identified in clinical trials were mild-to-moderate injection site reactions. Serious reactions were rare作者：S Russo·2024·被引用次数：20—A few years ago, SS-31 (also known as elamipretide)was tested in an American clinical trialas a potential first therapy for BTHS patients.. While specific SS-31 peptide dosage protocol and SS-31 peptide dose per day are determined by ongoing clinical studies, the general safety profile appears favorable, suggesting SS-31 peptide review often points to a good tolerability.SS-31 peptide enables mitochondrial targeting drug delivery Information on a SS-31 peptide dosage chart is typically found within the protocols of active clinical trials.Elamipretide – Knowledge and References

Future Directions and Ongoing Research

The scientific community continues to actively explore the full potential of SS-31.SS-31 treatment ameliorates cardiac mitochondrial ... Clinical trials are underway for SS-31, which is showing promise in managing mitochondrial myopathies and Barth syndrome. Researchers are also investigating novel modifications, such as introducing taurine substituents into SS-31, to enhance its anti-inflammatory effects and mitochondrial protective abilities. The development of SS-31 peptide as a component for targeted drug delivery is also an area of active research.FDA Grants Accelerated Approval to First Treatment for ... Despite the fact that no clinical trials are ongoing on this interesting molecule (referring to a specific context within a document), the broader field of SS-31 research is vibrant and dynamic.SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ...

In conclusion, the SS-31 peptide represents a significant advancement in the pursuit of treatments for a wide range of debilitating conditionsMitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, .... The ongoing exploration through various clinical studies and rigorous scientific investigation continues to unveil its multifaceted therapeutic capabilities, positioning it as a key player in the future of medicine.